Willemijn Hobo Selected Research

Minor Histocompatibility Antigens

1/2018	Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation.
1/2017	Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.
5/2015	Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18.
5/2015	siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
11/2014	Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy.
6/2014	Ex vivo generation of interstitial and Langerhans cell-like dendritic cell subset-based vaccines for hematological malignancies.
2/2013	Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation.
7/2012	B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
8/2011	PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.
11/2010	siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Willemijn Hobo Research Topics

Disease

31	Neoplasms (Cancer) 12/2023 - 11/2010
6	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 07/2012
5	Multiple Myeloma 11/2014 - 07/2012
4	Leukemia 01/2022 - 11/2010
4	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 10/2018
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2020 - 01/2016
2	Graft vs Host Disease (Graft-Versus-Host Disease) 05/2015 - 02/2013
2	Myeloid Leukemia (Leukemia, Myelocytic) 07/2012 - 08/2011
1	Goiter 10/2022
1	Thyroid Neoplasms (Thyroid Cancer) 10/2022
1	Lymphoma (Lymphomas) 01/2022
1	Carcinoma (Carcinomatosis) 02/2019
1	Ascites 10/2018
1	Hematologic Diseases (Blood Diseases) 01/2017
1	Residual Neoplasm 01/2017
1	Testicular Neoplasms (Testicular Cancer) 01/2016
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2016
1	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2016
1	Virus Diseases (Viral Diseases) 02/2013
1	B-Cell Lymphoma (Lymphoma, B Cell) 07/2012
1	Melanoma (Melanoma, Malignant) 02/2012
1	Prostatic Neoplasms (Prostate Cancer) 02/2012

Drug/Important Bio-Agent (IBA)

10	Minor Histocompatibility AntigensIBA 01/2018 - 11/2010
7	16-iodo-3-methylhexadecanoic acid (MIHA)IBA 01/2018 - 11/2010
6	VaccinesIBA 09/2023 - 11/2010
5	LigandsIBA 01/2022 - 08/2011
5	AntigensIBA 10/2016 - 02/2012
3	Interleukin-15 (Interleukin 15)IBA 01/2022 - 01/2017
3	CytokinesIBA 01/2021 - 11/2010
3	Small Interfering RNA (siRNA)IBA 12/2020 - 11/2010
2	Monoclonal AntibodiesIBA 12/2023 - 01/2022
2	Blocking AntibodiesIBA 12/2020 - 01/2018
2	AntibodiesIBA 07/2015 - 08/2011
2	Messenger RNA (mRNA)IBA 08/2013 - 02/2013
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 09/2023
1	IodineIBA 10/2022
1	Gemcitabine FDA Link 01/2021
1	Interferon-gamma (Interferon, gamma)IBA 11/2020
1	ALT-803IBA 10/2018
1	1,3- dihydro- 1- (1- ((4- (6- phenyl- 1H- imidazo(4,5- g)quinoxalin- 7- yl)phenyl)methyl)- 4- piperidinyl)- 2H- benzimidazol- 2- oneIBA 01/2018
1	ipatasertibIBA 01/2018
1	Decitabine FDA Link 01/2016
1	fludarabineIBA 01/2016
1	B-Cell Maturation AntigenIBA 08/2013
1	SurvivinIBA 08/2013
1	DNA (Deoxyribonucleic Acid)IBA 02/2013
1	Immunoglobulins (Immunoglobulin)IBA 07/2012
1	MucinsIBA 07/2012
1	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 02/2012
1	staphylococcal enterotoxin BIBA 02/2012
1	IpilimumabIBA 02/2012
1	Biomarkers (Surrogate Marker)IBA 02/2012
1	HLA Antigens (Human Leukocyte Antigens)IBA 11/2010

Therapy/Procedure

14	Stem Cell Transplantation 09/2023 - 11/2010
10	Therapeutics 01/2022 - 11/2014
7	Immunotherapy 12/2023 - 08/2013
3	Drug Therapy (Chemotherapy) 01/2021 - 07/2012
2	Aftercare (After-Treatment) 10/2022 - 02/2012
1	Transplantation 09/2023
1	Induction Chemotherapy 11/2021
1	Parenteral Infusions 02/2019
1	Ligation 01/2018
1	Precision Medicine 01/2018
1	Cell Transplantation 01/2016
1	Cell- and Tissue-Based Therapy (Cell Therapy) 05/2015
1	Hematopoietic Stem Cell Transplantation 07/2012